LYTIR

Company · FTH

Faeth Therapeutics, Inc.

Nasdaq's symbol directory lists FTH on Nasdaq as “Faeth Therapeutics, Inc. - Common Stock”.

In the 12 months to Nov 8, 2026: insiders bought on 8 occasions ($1.2M); 4 filings by holders of 5% or more; 3 company reports (Form 8-K, since May 26, 2026).

All insider filings at the SEC

Insider purchases and sales, by month (last 12 months)Insider purchases: $1.2M in total; Insider sales: $0 in total.Jun: Insider purchases $1.1MJul: Insider purchases $117KDecJanFebMarAprMayJunJulAugSepOctNov
Insider purchases above the line: $1.2MInsider sales below: $0
Dollar value of open-market purchases and sales reported on SEC Form 4, by the month traded. Sales include pre-arranged 10b5-1 plan sales.

Insider trades · SEC Form 4

Those inside the hall

Open-market purchases and sales only. Legs one person filed for one day are combined.

Who traded

  1. STEPHENSON BRIAN C, Chief Financial Officer bought on 7 days latest Jul 1, 2026 bought $1.1M
  2. Parikh Anand Kiran, President and CEO bought on 1 day latest Jun 22, 2026 bought $55K
Every trade (8)
  1. BUYSTEPHENSON BRIAN C, Chief Financial Officer bought Jul 1, 2026 5,000 shares 2 legs combined filing $117K
  2. BUYSTEPHENSON BRIAN C, Chief Financial Officer bought Jun 30, 2026 7,803 shares 3 legs combined filing $189K
  3. BUYSTEPHENSON BRIAN C, Chief Financial Officer bought Jun 29, 2026 831 shares filing $19K
  4. BUYSTEPHENSON BRIAN C, Chief Financial Officer bought Jun 26, 2026 6,250 shares 4 legs combined filing $156K
  5. BUYSTEPHENSON BRIAN C, Chief Financial Officer bought Jun 24, 2026 9,391 shares 4 legs combined filing $245K
  6. BUYSTEPHENSON BRIAN C, Chief Financial Officer bought Jun 23, 2026 9,230 shares 3 legs combined filing $225K
  7. BUYSTEPHENSON BRIAN C, Chief Financial Officer bought Jun 22, 2026 8,183 shares 5 legs combined filing $181K
  8. BUYParikh Anand Kiran, President and CEO bought Jun 22, 2026 2,806 shares filing $55K

Large holders · SEC Schedules 13D and 13G

Five percent and over

Anyone who comes to hold more than 5% of a company's voting shares must tell the SEC. A Schedule 13D is filed by a holder who may seek to influence the company; a 13G by one who states it is a passive investor. An amendment updates an earlier filing, and a stake reported as 0% means the holder says it has sold all, or nearly all, of its shares. Every recent 13D and 13G

  1. Khosla Ventures VI, LP filed Aug 14, 2026 Schedule 13G passive filing 10.2%
  2. Caligan Partners LP filed Aug 14, 2026 Schedule 13G/A passive filing 2.4%
  3. Trails Edge Capital Partners, LP filed Aug 14, 2026 Schedule 13G/A passive filing 2%
  4. StemPoint Capital LP filed Aug 14, 2026 Schedule 13G/A passive filing 0%

Company reports · SEC Form 8-K

In its own words

Current reports the company filed with the SEC; most items are due within four business days of the event. Each line lists the report's items by the SEC's own titles; the filing says what happened. Reports collected since May 26, 2026; every 8-K at the SEC.

  1. Results of operations and financial condition filing Nov 3, 2026
  2. Departure or appointment of directors or officers filing Oct 27, 2026
  3. Departure or appointment of directors or officers filing Sep 17, 2026

Sources: SEC EDGAR (Forms 4, 144 and 8-K) and STOCK Act periodic transaction reports. Filings can be late, amended or wrong at the source; see methodology.